A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD

Tom M A Wilkinson,1,2,3 Emmanuel Aris,4 Simon Bourne,1,5 Stuart C Clarke,1,3 Mathieu Peeters,4,6 Thierry G Pascal,4 Sonia Schoonbroodt,4 Andrew C Tuck,7 Viktoriya Kim,1,2 Kristoffer Ostridge,1,2 Karl J Staples,1,3 Nicholas Williams,1,2 Anthony Williams,3 Stephen Wootton,8 Jeanne-Marie Devaster,4 on behalf of the AERIS Study Group

INTRODUCTION

Acute exacerbations of COPD (AECOPD) are highly seasonal in incidence,1 2 which has important consequences for patients and healthcare services, which are often overstretched during winter seasons.3 One of the causes of this seasonality may be the increased incidence of respiratory viral infections.4

Bacterial pathogens are commonly identified in the lower airway of patients, both in the stable state and during acute exacerbations, with significant changes in prevalence of airway bacteria during AECOPD.4 5 Understanding the interaction between chronic bacterial airway infection and seasonal exposure to viruses may provide important insights into the mechanisms of exacerbation stratified for causal or associated pathogens and point to
potential therapies that prevent rather than treat events. Previous studies have identified human rhinovirus (HRV) infection as a key factor and that secondary bacterial infection, most commonly with non-typeable *Haemophilus influenzae* (NTHi), may be an important modulator of consequent inflammation and clinical severity. However, the nature of interactions between acute viral infection and chronic bacterial infection is not fully understood, nor are the effects of seasonality on the characteristics of exacerbation events.

In this prospective study, a well-characterised cohort of patients with COPD underwent sputum sampling each month and at exacerbation. Repeated identification of bacterial and viral airway infections with sensitive molecular diagnostic techniques allowed the influences of season and other factors on exacerbation occurrence to be examined over a full year. Insights into the aetiology of these important events were derived by examining the relationship between chronic airway bacterial infection and the associated risk and impact of acute viral infection.

**METHODS**

**Study design**

The Acute Exacerbation and Respiratory InfectionS in COPD (AERIS) study is a prospective, observational cohort study based at University Hospital Southampton (UHS), registered with ClinicalTrials.gov (NCT01360398). The study protocol has been published previously. This 2-year longitudinal epidemiological study assessed the contribution of changes in the COPD airway microbiome to the incidence of AECOPD. Patients aged 40–85 years with a confirmed diagnosis of COPD, categorised as moderate, severe or very severe, were recruited from UHS and referring practices from June 2011 to June 2012. AERIS was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice, and was approved by the Southampton and South West Hampshire Research Ethics Committee. All participants provided written informed consent. The protocol summary is available at [http://www.gsk-clinicalstudyregister.com](http://www.gsk-clinicalstudyregister.com) (study identifier, 114378). Full inclusion and exclusion criteria are listed in the online supplementary appendix.

We report results for the primary objective (estimation of the incidences of all-cause AECOPD and AECOPD with sputum containing bacterial pathogens detected by culture) for subjects followed over 1 year. We also describe secondary objective results on the incidences of bacterial and viral pathogens detected in AECOPD by PCR and in stable state COPD by culture (bacteria only) and PCR.

**Procedures**

Patients were followed monthly in the stable state and reviewed within 72 hours of onset of AECOPD symptoms. Exacerbations were detected using daily electronic diary cards. The definition of AECOPD, as described previously, and definitions of severity categories are provided in the online supplementary appendix.

Sputum samples were obtained by spontaneous expectoration or induced and were processed according to standard methods, as described in the online supplementary appendix.

**Statistical analysis**

The sample size calculation was described previously. First year results are presented for subjects included in the full cohort, defined as all patients considered by the investigator as eligible for study procedures and excluding those who withdrew consent at the first visit.

The percentage of stable-state and exacerbation-state sputum samples containing bacterial or viral pathogens (overall and by species) was calculated with 95% CIs. The 95% CI of the incidence rate was computed using the generalised linear model assuming a negative binomial distribution for the response variable with logarithm as link function and the logarithm of time for follow-up as an offset variable.

Post hoc conditional logistic regression models, stratified by subject, were used to identify the effect of the presence of pathogens in sputum on the odds of experiencing an exacerbation rather than stable COPD. This model does not take into account possible correlations between successive measures within each subject. However, tests of the fit of generalised estimating equations (GEEs) and generalised linear mixed models with the same logit link indicated that models assuming independence between observations within each subject provided a fit similar to those taking correlations into account. By stratifying by subject, the conditional logistic model has the added advantage of taking into account any confounding factors that remain constant over time (such as age, gender and COPD status) for each subject. Bacterial respiratory pathogens, HRV and any other virus were entered into the model to identify species associated with AECOPD, assessing new infection occurrences (detection after negative sputum sample at previous visit) as well as any infections (presence) and taking into account the seasonality. For the analysis of the effect of new infection occurrences, if the presence of bacteria or virus was not evaluated at the preceding stable/exacerbation visit, the last value observed before this visit was used. The seasons were divided into two: high season (October–March) and low season (April–September). The final conditional logistic models used were selected by a backward elimination procedure in which only statistically significant main or interaction effects (provided there were more than five observations in each combination of factors included in the interaction) were kept (p<0.05).

Seasonal rates of exacerbations, with the presence or new occurrence of bacterial or viral pathogens, were estimated post hoc by a GEE model with a logit link and assuming an exchangeable correlation matrix. Seasonal differences in incidence rates were tested by corresponding likelihood ratio tests. The GEE model with compound symmetry correlation (exchangeable structure) was chosen to detect differences between marginal frequencies. Investigation of the fit of different GEE models, using exchangeable, autoregressive or independent structure correlation matrices, found that the model assuming compound symmetry provided the best data fit.

Statistical analysis was performed using the SAS Drug Development platform V.4.3.2 (SAS Institute, Cary, North Carolina, USA).

**RESULTS**

Of 152 patients screened, 25 were excluded from the full cohort for reasons shown in figure 1 and 105 completed all follow-up visits up to month 12. The last patient visit of the study was in June 2014. Baseline characteristics of the full cohort are shown in table 1. The patients’ age range was 42–83 years and most had moderate (44.9%) or severe (40.2%) COPD. Almost half (48.8%) had more than two documented exacerbations in the year before enrolment. Bronchiectasis, which was assessed at enrolment by high-resolution CT scan, was present in a minority of patients (10 of 127 patients; 7.9%).

During the first year of follow-up, a total of 355 acute exacerbations were recorded and 47.2% of patients had more than
two exacerbations (see online supplementary table S1). The mean exacerbation rate was 3.04 (95% CI 2.63 to 3.50) per patient-year. Most exacerbations (304, 85.6%) were moderate in severity, 31 (8.7%) were mild and 20 (5.6%) were severe.

The rate of sputum collection was high at stable (79.1%) and exacerbation states (91.3%) (figure 1). An antibiotic was administered before sputum collection in 1.1% (11 of 959) stable and 8.6% (28 of 324) exacerbation samples. Most AECOPD samples (71%) were collected within 2 days of the start of exacerbation symptoms. Overall, 48.9% of stable-state and 58.8% of exacerbation-state samples were positive for bacteria by culture (figure 2A, see online supplementary table S2). For PCR-detected bacteria, corresponding proportions were 56.6% at stable state and 67.1% at exacerbation (figure 2B; see online supplementary table S2). The most common species isolated were NTHi, Streptococcus pneumoniae and Moraxella catarrhalis. For a small proportion of samples (10.6%) with cultured isolates phenotypically identified as H. influenzae, the lgtC/P6 PCR did not confirm the presence of true H. influenzae (see online supplementary appendix). Of 230 sputum samples where S. pneumoniae was identified phenotypically by culture and optochin sensitivity testing, 147 tested negative by PCR.

Preliminary bacterial genome sequencing on a subset of isolated strains identified phenotypically as S. pneumoniae showed that the colonies belonged to the pneumococcus-like viridans group and were mainly S. pseudopneumoniae (data not shown). The proportion of samples that were NTHi or M. catarrhalis-positive was higher at exacerbation than stable state (figure 2A and B). NTHi was highly prevalent at exacerbation; 70.3% (95% CI 60.4 to 79.0) of patients had at least one exacerbation that was NTHi-positive by PCR (56.7% (46.7 to 66.4) by culture) (see online supplementary table S3).

The proportion of sputum samples positive for at least one virus increased from 13.6% at stable state to 41.3% at exacerbation (figure 2C, see online supplementary table S2). The most common species isolated was HRV, detected in 6.2% and 23.0% of stable and exacerbation samples, respectively. Nearly half (46.5%; 95% CI 36.5 to 56.7) of patients had at least one exacerbation that was HRV-positive during the year of follow-up (see online supplementary table S4). There was also increased simultaneous bacterial and viral presence at exacerbation compared with stable state when determined by culture (24.9% vs 8.6%) and PCR (29.2% vs 9.1%) (figure 3).

The distribution of AECOPD cases with sputum samples showed seasonal variations (figure 4, see online supplementary figure S1). The percentage of visits where an exacerbation was recorded increased from 20.6% in low season (April-

**Table 1** Characteristics of the patients at enrolment (full cohort, year 1)

| Characteristic                                | N=127            |
|-----------------------------------------------|------------------|
| Age (years) at enrolment, mean±SD             | 66.8±8.6         |
| Female sex, n (%)                             | 59 (46.5%)       |
| Smoking history pack-years, median (IQR)      | 47.0 (33.7–60.0) |
| Medication for COPD, n (%)                    | 127 (100%)       |
| Influenza vaccination during previous year, n (%) | 114 (89.8%) |
| Pneumococcal vaccination during previous year, n (%) | 12 (9.4%) |
| COPD status, GOLD stage, n (%)                |                  |
| Mild                                          | 0 (0%)           |
| Moderate                                      | 57 (44.9%)       |
| Severe                                        | 51 (40.2%)       |
| Very severe                                   | 19 (15.0%)       |
| BODE index, median (IQR)                      | 4 (2–6)          |
| TLCO predicted/actual (mmol/kPa/min), median (IQR) | 7.9 (7.2–8.8)/4.5 |
| Number of subjects reporting exacerbations in preceding 12 months, n (%) |                  |
| One exacerbation                              | 28 (22.0%)       |
| Two exacerbations                             | 37 (29.1%)       |
| Three exacerbations                           | 25 (19.7%)       |
| Four or more exacerbations                    | 37 (29.1%)       |
| Number of exacerbations in preceding 12 months, mean±SD/median (IQR) | 3.1±2.3/2 (2–4) |
| Number of exacerbations in preceding 12 months according to severity, mean±SD | 46.4±15.2 |
| Mild                                          | 0.5±1.2          |
| Moderate                                      | 2.3±1.9          |
| Severe                                        | 0.4±0.6          |

**BODE index, body mass index, airflow obstruction, modified Medical Research Council Dyspnoea Scale, exercise capacity index; GOLD, Global Initiative for Chronic Obstructive Lung Disease; N, total number of subjects; TLCO, transfer factor of the lung for carbon monoxide.**
Figure 2  Percentage of culture-positive or PCR-positive sputum samples at stable state and exacerbation state (full cohort, year 1). (A) Percentage of sputum samples positive for bacteria by culture. (B) Percentage of sputum samples positive for bacteria by PCR*. *Group A streptococcus (Streptococcus pyogenes) was not detected. (C) Percentage of sputum samples positive for virus by PCR.

HRV, human rhinovirus; NTHi, non-typeable Haemophilus influenzae.

Wilkinson TMA, et al. Thorax 2017;0:1–9. doi:10.1136/thoraxjnl-2016-209023
September) to 29.3% in high season (October–March) (p<0.001, see online supplementary table S5), corresponding to an increase from 126 to 194 exacerbations. A similar effect was observed for exacerbations in which bacterial or viral aetiology was detected (15.9% of all visits at low season, 25.3% at high season; p<0.001). For exacerbations where no bacteria or viruses were detected, there was no significant difference between low and high seasons (4.6% vs 3.9%, p=0.513).

Figure 3  Percentage of sputum samples that contained more than one bacterial or viral species by culture or PCR at stable state and exacerbation (full cohort, year 1). N, Number of samples identified in each category.

Figure 4  Seasonal distribution of acute exacerbations of COPD (AECOPD) cases with sputum samples: total number and number of cases positive by PCR for non-typeable Haemophilus influenzae (NTHi), M. catarrhalis, human rhinovirus (HRV) or any viral species, and cases negative for bacteria and viruses (full cohort year 1; month of follow-up considered regardless of year).
The risk of AECOPD in relation to pathogen detection was examined with conditional logistic regression models stratified by subject, meaning that there was no need to adjust for time-invariant covariates. No statistically significant relationship was found between the presence (by culture or PCR) of S. pneumoniae, Staphylococcus aureus or Pseudomonas aeruginosa and risk of exacerbation. The OR of experiencing an AECOPD rather than being in stable state was significant for M. catarrhalis detected by culture (5.09 (95% CI 2.76 to 9.41), figure 5A) and PCR (3.52 (2.12 to 5.83), figure 5B). The percentage of visits in which M. catarrhalis was detected increased from low to high season (4.9% vs 8.7%; p=0.005, see online supplementary table S6), suggesting increased M. catarrhalis presence during the high season may partly account for the seasonal increase in exacerbations. However, no additional interaction with season was detected, suggesting that the strength of effect of M. catarrhalis infection on the likelihood of AECOPD was constant throughout the year.

For NTHi detected by culture, but not by PCR, a statistical interaction was detected with season; so, ORs were calculated for the high and low seasons. The OR for exacerbation was significant (3.04 (95% CI 1.80 to 5.13)) in high season but not significant in low season (1.22 (0.68 to 2.22)) (figure 5A). This suggested that susceptibility to exacerbation in the presence of NTHi is greater in high season, which is when NTHi detection is also higher (35.6% during high season vs 28.6% during low season; p=0.010; see online supplementary table S6). Interestingly, the effect of NTHi presence detected by PCR (but not by culture) on the likelihood of AECOPD was found to be higher when HRV was also detected (OR 5.18 (95% CI 1.92 to 13.99)) than when HRV was absent (OR 1.69 (1.10 to 2.59); interaction p=0.031) (figure 5B). The percentage of visits with any virus detected was statistically significantly higher at high season (p<0.001), as was the percentage of visits in which any virus other than HRV was detected (p=0.002), but this was not the case when considering HRV presence only (see online supplementary table S6). ORs for exacerbation were significant in the presence of HRV for any other virus (figures 5A and B), with no statistical interaction with season. This suggests that, although viral infection rates varied overall with season, the risk of a particular viral detection event being associated with an exacerbation did not differ with the time of year, except perhaps for HRV because of the higher prevalence of NTHi during high season.

We also explored the effect of bacteria detected as new occurrences on the likelihood of experiencing an AECOPD. The OR of being in an exacerbation rather than stable state was significant for new occurrences of NTHi (detected by culture), M. catarrhalis (culture and PCR) and HRV or other viruses (figures 5A and B). No interaction with season was found. The percentage of visits with new NTHi occurrences detected by culture was increased during high season compared with low season (11.8% vs 8.5%, p=0.043, see online supplementary table S6).

To test the robustness of these results, analyses were also performed on the cohort of subjects who had a sputum sample taken and measured on each stable and exacerbation visit (complete cases only) or the cohort of subjects that excluded those without a tested sputum sample at the previous visit. The results obtained from these analyses were similar to those of the primary analyses (data not shown).

Bacterial load data suggested that NTHi and M. catarrhalis loads at exacerbation tended to be higher during high season compared with low season (p=0.015 and 0.048, respectively), but the average difference was less than a factor of 10 (see figures 5A and B), supporting the conclusion that the observed increase in exacerbations during high season was not due to an increase in bacterial loads.
DISCUSSION
In this prospective, observational cohort study, repeated measures of both bacterial and viral infection were taken over 1 year from patients with well-characterised COPD. Identification of *M. catarrhalis* and NTHi, but no other bacteria, was associated with a heightened risk of exacerbation. There was an additional risk of exacerbation from October to March associated with NTHi infection driven by both significantly more frequent detection and a greater specific risk of exacerbation in comparison with low season. With *M. catarrhalis*, a significant seasonal pattern of detection was also seen, but in contrast to NTHi, the risk of exacerbation when *M. catarrhalis* was detected did not differ with the time of year. Interestingly, no seasonal effect was detected on AECOPD risk with new occurrences of bacterial pathogens (NTHi or *M. catarrhalis*), suggesting that longer term colonisation with NTHi may contribute to seasonal susceptibility to AECOPD rather than its acquisition. Although viral infection rates overall were highly seasonal, the prevalence of HRV infection was more evenly spread throughout the year. The study also highlighted an interaction between HRV and NTHi infection and the risk of AECOPD, and that bacterial loads at exacerbation were higher in the period that included winter. These results provide novel insights into the dynamics of infection in COPD, suggesting that exacerbations are associated with seasonal and non-seasonal infections. The seasonal burden of infective AECOPD appears to be driven partly by the effect of acute HRV infection on a background of chronic NTHi infection, an effect size that has been quantified for the first time in the AERIS study. This may have more of an impact on the seasonality of AECOPD than acquisition of NTHi or *M. catarrhalis* throughout the year.

The exacerbation frequency for the cohort of 127 patients during the study year was similar to that in the year before enrolment, suggesting a relatively constant phenotype. This was in line with other studies that identified the number of exacerbations in the previous year as a significant predictive factor. Most exacerbations were moderate in severity, possibly because patients were monitored closely via daily electronic diary cards, enabling early capture and rapid treatment of exacerbation events.

At stable state, the most prevalent bacterial species identified were NTHi, *M. catarrhalis* and *S. pneumoniae*, consistent with other studies. The prevalence of NTHi and *M. catarrhalis* increased at exacerbation. Previous studies also reported an association between exacerbation and a shift in the microbiome towards enrichment of Proteobacteria. In our study, there was a discrepancy between culture and PCR identification of *S. pneumoniae*, with 64% of colonies identified as *S. pneumoniae* by culture subsequently identified by PCR and molecular methods as predominantly *S. pseudopneumoniae*. This was unexpected, but may be explained by the specificity of the target *lytA* gene used in our PCR method; other target genes (*ply* or *psaA*) are less specific in differentiating streptococcal species. We found that *S. pneumoniae* and closely related species did not contribute to exacerbation occurrence, but cannot exclude the possibility of a role at a later stage, since AECOPD events might have been identified and treated early.

Among the viral species identified, HRV was most prevalent, with 23% of sputum samples positive at exacerbation. Almost half of patients had at least one HRV-positive exacerbation. The differential detection rate for enterovirus between stable and exacerbation samples may be related to the biology of infection; enteroviruses other than HRV might also have been present, causing less symptomatic AECOPD than HRV subtypes. Other viruses were detected infrequently but with prevalences that tended to be higher at exacerbation than stable state, as reported previously. This supports evidence suggesting that respiratory viruses initiate a large proportion of acute exacerbations. We also noted a large increase in bacterial and viral coinfection at exacerbation compared with stable state. In various studies, this coinfection has been associated with more marked lung function impairment and longer hospitalisations than only bacterial or viral infections.

Post hoc logistic regression analyses revealed differences among the pathogens in terms of mechanism of effect in AECOPD. For cases in which pathogens were a new occurrence at exacerbation, *M. catarrhalis* had an effect that was independent of viral and seasonal effects. This suggests an association between acquisition of *M. catarrhalis* strains and exacerbation. In contrast, new NTHi occurrences appear to play a less important role, and analyses of its presence showed an interaction with HRV and an effect in AECOPD that is partly explained by season. It is likely that complex mechanisms exist for the associations among NTHi, HRV and season. Bacterial colonisation is associated with airway inflammation in stable COPD, which is likely to increase the likelihood of exacerbation and may also increase the risk of lower airway viral infection. There is also evidence of interactions between lower airway bacterial and rhinoviral infection in AECOPD and stable COPD. The exact mechanisms by which HRV or other viral infections lead to a change in the balance of microbiota and host immunity may contribute to increased detection rates of NTHi, inflammation and exacerbation. Acute viral infection can disrupt host immunity by affecting epithelial barrier function, limiting macrophage phagocytosis and directly impacting on innate responses to bacteria. While this may lead to a more permissive niche for outgrowth of more opportunistic pathogens, such as NTHi, it is likely that the interplay of bacterial, viral and host interactions is more complex than such a description of cause and effect. The airway microbiome has been described in a number of recent studies, with COPD characterised by a loss of bacterial diversity and dominance of certain species. Furthermore, experimental studies highlight the effects of airway bacterial pathogens on responses to subsequent viral infection.

Indeed, in our own data, viruses were detectable in both stable and exacerbation states, although the rates varied. Hence, the dynamics driving the ultimate consequence of this abnormal host pathogen interaction, an exacerbation, will require yet further study using molecular tools and sophisticated modelling to assess the impacts of microbial communities and acute infections.

Few other studies have addressed the complexity of the microbiological components of COPD or employed real-time electronic tracking of symptoms to identify AECOPD and potential aetiological triggers. Moreover, other longitudinal studies have not examined viral and bacterial infection rates over the same period of time. The most current technology was used to identify respiratory microorganisms including highly sensitive PCR, increasing both the detection rates and specificity for identifying key pathogens. The selection of patients with a history of exacerbations limits the generalisability of the data to a more heterogeneous population, and additional studies are required to determine if our results can be extrapolated to other COPD phenotypes. Moderate
excursions were largely represented probably because close monitoring and early therapeutic intervention are likely to have led to an attenuation in overall severity. We also acknowledge the potential for missing variable results, although sputum sampling rates were very high for a study of this nature. Moreover, results are only presented for subjects followed for the first year of this 2-year study. While further analysis of longer term data is planned, the subject populations of year 1 and year 2 were dissimilar because of the number of dropouts that occurred during the study (105 subjects completed 1 year, and 88 completed 2 years). The protocol was designed to maintain the cohort, with recruitment continuing up to the beginning of the second year to ensure an adequate number of individual exacerbations was captured. Hence, while the cohort was relatively stable for the first year, it changed during the second. Attrition of subjects and sample points from this relatively intensive study affected the cohort make-up and hence the second year results. In addition, with the changing pattern of clinical practice in the second year of the study, some of the more frequent exacerbators were commenced on long-term macrolide therapy, which would have altered airway microbial patterns. For this longitudinal analysis of repeated samples within individuals, the first year dataset was therefore selected.

Another limitation of the study is that exact timing of sputum collection was not recorded in relation to initiation of antibiotic or oral corticosteroid treatment following AECOPD onset. As a consequence, we cannot exclude the possibility that initiation of treatment during AECOPD could have had an impact on the bacterial culture results and, to a lesser extent, PCR results. However, the number of patients concerned is likely to be small because sputum collection occurred within 2 days of the start of AECOPD symptoms for most patients. Bacterial or viral pathogen detection was not possible in patients who were unable to produce sputum. We therefore cannot exclude the possibility that infection rates in this group were different to those in patients who did provide sputum samples. This could not be adjusted for in the model and highlights the need for non-invasive means of measuring biomarkers which predict infectious aetiology in patients with COPD.

We also cannot exclude the possibility of confounding of findings by participant characteristics that varied over time. We consider this unlikely since patient characteristics associated with COPD, such as disease severity, usually do not vary significantly over a 1-year period, and other characteristics, such as inflammatory factors, are closely related to the aetiology of the disease and cannot be adjusted for in the model. The results presented on seasonality were obtained by post hoc analyses of association. Studies are needed to confirm these results and describe more precisely the effect of airway bacterial infection in relation to viruses on AECOPD during the year.

In conclusion, the AERIS study has identified that NTHi, *M. catarrhalis* and HRV infections have a key role in AECOPD, and for the first time has shown that seasonal risk of exacerbation differs depending on the bacterial pathogen concerned. The association with longer term NTHi infection, alone and in combination with HRV infection, may be key to the seasonality of AECOPD. Understanding the mechanisms driving the complex interactions between chronic bacterial airway infection and seasonal exposure to viruses will provide insights necessary to develop potential therapies to prevent AECOPD.

**Author affiliations**

1. Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, UK

2. Southampton NIHR Respiratory Biomedical Research Unit, Southampton General Hospital, Southampton, UK

3. Wessex Investigational Sciences Hub, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, UK

4. GSK, Ware, Belgium

5. Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital, Portsmouth, UK

6. ThromboGenics NV, Leuven, Belgium

7. Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK

8. Southampton NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK

**Acknowledgements** The authors thank the patients who participated in this study and the clinical staff without whom the study could not have been performed. The authors thank the DDL Diagnostic Laboratory (Rijswijk, The Netherlands) and the GSK Clinical Laboratory Sciences team for their contribution to the study assays. The authors thank the GSK teams that worked on the monitoring, the follow-up, the logistics of the samples as well as the data management. The authors also thank Géraldine Devon and Sophie Timmery (XPE Pharma & Science, on behalf of GSK) for coordination and editorial support, and Joanne Knowles (independent writer, on behalf of GSK) for writing assistance. The study was funded by GlaxoSmithKline Biologicals SA.

**Collaborators** The AERIS Study Group: J Alnajar, R Anderson, E Aris, WR Ballou, A Barton, S Bourne, M Caubet, SC Clarke, D Cleary, C Cohet, N Coombs, K Cox, J-D Devaster, V Devine, N Devos, E Dienne, T Elliott, R Gladstone, S Harden, J Jufferies, V Kim, S Mesma Veia, P Morris, K Oxtridge, TG Pascal, M Peeters, S Schoonvanscoot, K Stapoles, A Tuck, L Welch, V Veynans, TMA Wilkinson, AP Williams, N Williams, C Woelk, M Wojtas, S Wootton. All members of the AERIS Study Group were involved in the planning, conduct and/or reporting of the work described in the article.

**Contributors** JM-D, TGP, SB, SW, SS, ACT, SCC, AW and TMAW conceived and designed the study. EA, J-MD, TGP, MP, SS, SB, SW, ACT, NW, KO, KJS, SCC, VK, AW and TMAW collected or generated the data. EA, J-MD, TGP, MP, SB, SW, NW, KO, KJS, SCC, VK, AW and TMAW analysed or interpreted the data. TMAW, EA, SB, SCC, MP and J-MD are members of the core writing team. TMAW, EA, SB, SCC, MP and J-MD are members of the AERIS study steering committee. All authors contributed substantially to the development of the manuscript and approved the final version.

**Funding** The study funder, GlaxoSmithKline Biologicals SA, designed the study in collaboration with the investigators, and coordinated collection, analysis and interpretation of data. The investigators obtained data and cared for the study participants. The authors had full access to all data in the study, contributed to the writing of the report and had final responsibility for the decision to submit for publication.

**Competing interests** TMAW has received reimbursement for travel and meeting attendance from Boehringer Ingelheim and AstraZeneca, outside of the submitted work. SB received grants and assistance in travel to conferences from GSK outside of the submitted work. SCC received a grant from Pfizer outside of the submitted work. KJS received grants from Asthma UK (08/026) and BMA HC Roscoe Award outside of the submitted work, and he has a patent PCT/GB2010/050821 ‘Ev 'Ex Vivo Modelling of Therapeutic Interventions’ pending. EA, J-MD, SS and TGP hold shares/restricted shares in the GSK group of companies. KO, KJS, VK, NW, KO, SW and TMAW received an institutional grant from the GSK group of companies to conduct this study. AW and AT declare no conflicts of interest.

**Ethics approval** Southampton and South West Hampshire Research Ethics Committee.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
3 Donaldson GC, Wedzicha JA. The causes and consequences of seasonal variation in COPD exacerbations. *Int J Chron Obstruct Pulmon Dis* 2014;9:1101–10.
4 Garcha DS, Thurston SJ, Patel AR, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. *Thorax* 2012;67:1075–80.
5 Huang YJ, Sethi S, Murphy T, et al. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease. *J Clin Microbiol* 2014;52:2813–23.
6 Wilkinson TM, Hurst JR, Perera WR, et al. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. *Chest* 2006;129:317–24.
7 Papi A, Bellittaro CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. *Am J Respir Crit Care Med* 2006;173:1114–21.
8 Bourne S, Cohet C, Kim V, et al. Acute Exacerbation and Respiratory Infections in COPD (AERIS): protocol for a prospective, observational cohort study. *BMJ Open* 2014;4:e004546.
9 Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 2013;187:347–65.
10 Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med* 2010;363:1128–38.
11 Bertens LC, Reitsma JB, Moons KG, et al. Development and validation of a model to predict the risk of exacerbations in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2013;8:493–9.
12 Müllerová H, Shukla A, Hawkins A, et al. Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. *BMJ Open* 2014;4:e006171.
13 Kerkhof M, Freeman D, Jones R, et al. Predicting frequent COPD exacerbations using primary care data. *Int J Chron Obstruct Pulmon Dis* 2015;10:2439–50.
14 Bafadhel M, Haldar K, Barker B, et al. Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function. *Int J Chron Obstruct Pulmon Dis* 2015;10:1075–83.
15 Barker BL, Haldar K, Patel H, et al. Association between pathogens detected using quantitative polymerase chain reaction with airway inflammation in COPD at stable state and exacerbations. *Chest* 2015;147:46–55.
16 Sethi S. Infection as a comorbidity of COPD. *Eur Respir J* 2010;35:1209–15.
17 Wang H, Gu X, Weng Y, et al. Quantitative analysis of pathogens in the lower respiratory tract of patients with chronic obstructive pulmonary disease. *BMC Pulm Med* 2015;15:94.
18 Molyneaux PL, Mallia P, Cox MJ, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2013;188:1224–31.
19 Millares L, Ferrari R, Gallego M, et al. Bronchial microbiome of severe COPD patients colonised by *Pseudomonas aeruginosa*. *Eur J Clin Microbiol Infect Dis* 2014;33:1101–11.
20 Carvalho MGS, Tondella ML, McCaustland K, et al. Evaluation and improvement of real-time PCR assays targeting *Ia* and *psaA* genes for detection of pneumococcal DNA. *J Clin Microbiol* 2007;45:2460–6.
21 Zwaans WA, Mallia P, van Winden ME, et al. The relevance of respiratory viral infections in the exacerbations of chronic obstructive pulmonary disease—a systematic review. *J Clin Virol* 2014;61:181–8.
22 George SN, Garcha DS, Mackay AJ, et al. Human rhinovirus infection during naturally occurring COPD exacerbations. *Eur Respir J* 2014;44:87–96.
23 Clark TW, Medina MJ, Batham S, et al. C-reactive protein level and microbial aetiology in patients hospitalised with acute exacerbation of COPD. *Eur Respir J* 2015;45:76–86.
24 MacDonald M, Korman T, King P, et al. Exacerbation phenotyping in chronic obstructive pulmonary disease. *Respirology* 2013;18:1280–1.
25 Dai MY, Qiao JP, Xu YH, et al. Respiratory infectious phenotypes in acute exacerbation of COPD: an aid to length of stay and COPD Assessment Test. *Int J Chron Obstruct Pulmon Dis* 2015;10:2257–63.
26 Murphy TF, Parameswaran GI. Moraxella catarrhalis, a human respiratory tract pathogen. *Clin Infect Dis* 2009;49:124–31.
27 Mallia P, Froott J, Statero R, et al. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2012;186:1117–24.
28 Ohrui T, Yamaya M, Sekizawa K, et al. Effects of rhinovirus infection on hydrogen peroxide-induced alterations of barrier function in the cultured human tracheal epithelium. *Am J Respir Crit Care Med* 1998;158:241–8.
29 Oliver BG, Lim S, Wark P, et al. Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages. *Thorax* 2008;63:519–25.
30 Segal LN, Rom WN, Weiden MD. Lung microbiome for clinicians. New discoveries about bugs in healthy and diseased lungs. *Ann Am Thorac Soc* 2014;11:108–16.
31 Gulraiz F, Bellinghausen C, Bruggeman CA, et al. Haemophilus influenzae increases the susceptibility and inflammatory response of airway epithelial cells to viral infections. *FASEB J* 2015;29:849–58.
32 Bellinghausen C, Gulraiz F, Heinemann AC, et al. Exposure to common respiratory bacteria alters the airway epithelial response to subsequent viral infection. *Respir Res* 2016;17:68.
33 Heinitz A, Haarmann H, Zahradnik S, et al. Moraxella catarrhalis decreases antiviral innate immune responses by down-regulation of *TIR3* via inhibition of p53 in human bronchial epithelial cells. *FASEB J* 2016;30:2426–34.
34 Sethi S, Evans N, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. *N Engl J Med* 2002;347:465–71.
35 Desai H, Escherberger K, Wrona C, et al. Bacterial colonization increases daily symptoms in patients with chronic obstructive pulmonary disease. *Ann Am Thorac Soc* 2014;11:303–9.
36 Sethi S, Sethi R, Escherberger K, et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2007;176:356–61.